Outlook Therapeutics, Inc.
OTLK· Nasdaq
OTLKOutlook Therapeutics, Inc.
Filed May 15, 2026 · 10-Q · 45 days after period end · 0001104659-26-062632
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$4.45M | -$46.36M | -$114.29M | -$6.65M |
| EPS Diluted | -$0.05 | -$1.50 | -$8.01 | -$0.52 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 15, 2026 · 45 d after period end
